10-Q: Solitron Devices Q3 Sales Surge 49%, Backlog Doubles

Solitron Devices, Inc. reported a significant 49% increase in net sales for the third quarter of fiscal year 2026, driven by strong bookings and a doubling of its backlog, despite a decline in nine-month net income.

Summary

• Net sales for the three months ended November 30, 2025, increased by 49% to $5.022 million, compared to $3.369 million in the prior year.
• Net sales for the nine months ended November 30, 2025, increased by 7% to $11.708 million, compared to $10.917 million in the prior year.
• Net bookings for the three months ended November 30, 2025, surged by 73% to $13.907 million, and for the nine months, increased by 78% to $21.028 million, primarily due to an AMRAAM order.
• Backlog as of November 30, 2025, more than doubled, increasing by 124% to $27.482 million from $12.277 million a year prior.
• Gross profit margin improved for the three-month period to 34% (from 30%) but declined for the nine-month period to 25% (from 31%) due to higher material costs and increased tariffs.
• Operating income for the three months ended November 30, 2025, increased by 185% to $929,000, but for the nine months, it decreased by 77.8% to $260,000, attributed to weak first and second quarters.
• Net income for the three months ended November 30, 2025, was $653,000, up from $266,000, while net income for the nine months ended November 30, 2025, significantly decreased to $83,000 from $872,000.
• The company repurchased 3,850 shares of common stock for approximately $63,000 during the nine months ended November 30, 2025, under its $2 million stock repurchase program.
• CEO, COO, CFO, and non-employee directors received 14,000 immediately vested stock grants on August 13, 2025, valued at $225,000.
• COO and President Mark Matson purchased 50,000 shares at $14.50 and 5,000 additional shares subsequent to quarter end as part of his updated employment agreement.
• Cash and cash equivalents decreased to $3.602 million as of November 30, 2025, from $4.099 million as of February 28, 2025, primarily due to a $1.650 million long-term investment purchase.
• Working capital decreased to $7.906 million as of November 30, 2025, from $8.594 million as of February 28, 2025.

Sentiment

Score: 5

Explanation: While the company demonstrated strong Q3 performance with significant sales growth and a doubling of backlog, the nine-month results show a substantial decline in net income and operating income, primarily due to weak earlier quarters and margin compression from higher costs and tariffs. The un-remediated material weakness in internal controls also adds a layer of concern, balancing the positive future outlook from the backlog.

Positives

• Strong Q3 FY26 net sales growth of 49% to $5.022 million.
• Significant increase in net bookings for both the three-month (73% to $13.907 million) and nine-month (78% to $21.028 million) periods.
• Backlog more than doubled, increasing by 124% to $27.482 million, indicating strong future revenue potential.
• Improved gross profit margin in Q3 FY26 (34% vs 30%).
• Improved SG&A as a percentage of net sales in Q3 FY26 (16% vs 20%).
• Substantial increase in Q3 FY26 operating income (185% to $929,000) and net income (145% to $653,000).
• No known material current, pending, or threatened litigation.
• Management expects current liquidity to be sufficient for the next twelve months.

Negatives

• Nine-month net income significantly decreased by 90.5% to $83,000 (from $872,000) compared to the prior year.
• Nine-month operating income decreased by 77.8% to $260,000, attributed to weak performance in the first two quarters of fiscal 2026.
• Nine-month gross profit margin declined to 25% (from 31%) due to higher material costs and increased tariffs.
• Nine-month cost of sales as a percentage of net sales increased to 75% (from 69%).
• Nine-month SG&A as a percentage of net sales increased to 23% (from 21%).
• Cash and cash equivalents decreased by $497,000 during the nine-month period.
• Working capital decreased by $688,000 during the nine-month period.
• Unrealized losses on investments of ($433,000) for the nine months ended November 30, 2025.
• Material weakness in internal control over financial reporting from the prior annual report has not yet been remediated and tested for effectiveness.

Risks

• Substantial customer concentration, with the top three customers (ConMed Linvatec, RTX (Raytheon), L3Harris) accounting for 75% of Q3 FY26 revenues and the top two (ConMed Linvatec, RTX (Raytheon)) accounting for 62% of 9-month FY26 revenues.
• Dependence on government contracts (52% of Q3 FY26 sales, 48% of 9-month FY26 sales), which are subject to termination, price renegotiations, and regulatory compliance.
• Complex manufacturing processes may lead to lower yields and reduced revenues.
• Inability to obtain qualified supplies of raw materials, parts, and finished components on a timely basis and at a cost-effective price.
• Increased international tariffs and threats of international tariffs, which have already impacted gross profit margins.
• Potential inability to successfully execute acquisition strategy.
• Continued inflationary pressures could reduce margins and future business.
• Changes in government policy, economic conditions, technology, or reduction in government spending.
• Inventory obsolescence risk, with significant reserves already in place ($5.011 million total reserve).
• Highly competitive business environment.
• Dependence on recruitment and retention of qualified personnel.
• Exposure to potentially significant product liability risk.
• Inability to protect proprietary technologies or maintain the right to use certain technologies.
• Uncertainty regarding sufficient capital resources for necessary investments in manufacturing technology and equipment.
• Risk of impairment of substantial investments in property, plant, and equipment.
• Risk due to adverse financial condition of one or more customers.
• International operations expose the company to material risks, including U.S. export laws.
• Security breaches and other disruptions could compromise information integrity.
• Fluctuation in common stock price.
• Uncertainty of future cash dividend payments or share repurchases.
• Compliance with "conflict minerals" regulations could limit supply and increase costs.
• Failure to fully remediate and test controls related to the material weakness in internal control over financial reporting.
• A distributor agreement with a termination clause allows for a full credit for $1.029 million of inventory upon 60 days' notice.

Future Outlook

Management anticipates capital expenditures of approximately $250,000 over the next twelve months and expects cash from operations and existing cash and cash equivalents to be sufficient to fund these needs. The company may pursue acquisitions, additional product lines, and investments in common stocks or higher-yielding debt instruments to utilize net operating loss carryforwards and will continue to consider additional share repurchases.

Management Comments

• The increase in net sales was largely due to increased backlog in fiscal year 2026 as compared to fiscal year 2025 and the associated delivery dates of those orders.
• Net bookings... primarily due to an increase in price and volume on the AMRAAM order from our largest customer, and to a lesser extent the variable timing on the receipt of orders.
• The decrease in [nine-month] income was due to weak first and second quarters in fiscal 2026 as the Company ramped up production.
• We expect our sole sources of liquidity over the next twelve months to be cash from operations and cash and cash equivalents, if necessary.
• We anticipate that our capital expenditures required to sustain operations will be approximately $250,000 during the next twelve months and that our cash from operations and cash and cash equivalents, if necessary, will be sufficient to fund these needs for the next twelve months.
• Based on various factors, including the Company's desire to fully utilize its current net operating loss carryforwards, the Company may seek out acquisitions, additional product lines, and/or invest a portion of its cash into common stocks or higher yielding debt instruments.
• The Company will also continue to consider additional share repurchases under the Company's stock repurchase program subject to market conditions, corporate liquidity requirements and priorities and other factors as may be considered in the Company's sole discretion.
• We believe it is highly unlikely that the distributor would exercise termination [of the agreement with a full credit clause].

Industry Context

Solitron Devices operates in the specialized military and aerospace semiconductor components market, which is heavily influenced by government contracts and defense spending. The significant increase in backlog, particularly from a major AMRAAM program order, suggests robust demand within this niche, potentially driven by ongoing defense initiatives. However, the impact of higher material costs and increased tariffs on nine-month gross margins indicates broader supply chain and economic pressures affecting the manufacturing sector, even for specialized components.

Corporate Governance

Legal Proceedings

• No known material current, pending, or threatened litigation as of November 30, 2025.

Related Party Transactions

• Purchases of die and wafers from ES Components, where Mr. Aubrey (a director) is a minority owner and an immediate family member of the majority owner.
• For the three months ended November 30, 2025, purchased $52,000 of die from ES Components.
• For the nine months ended November 30, 2025, purchased $110,000 of die from ES Components.
• No sales to ES Components for the three or nine months ended November 30, 2025, or 2024.

Stakeholder Impact

• Shareholders: Mixed impact. Strong Q3 and backlog suggest future growth, but significant decline in nine-month profitability and un-remediated internal control weakness are concerns. Stock repurchase program and executive stock purchases could influence share price.
• Employees: Stock grants to key executives and directors, and an updated employment agreement for the COO, indicate efforts to incentivize and retain key personnel. Higher corporate salaries and sales expenses suggest investment in human capital.
• Customers: Increased backlog and bookings, particularly from government contracts (AMRAAM program), indicate strong demand for the company's specialized products. Customer concentration remains high.
• Suppliers: Dependence on a few major suppliers (two suppliers provided 37% of production materials in Q3 FY26) creates concentration risk. Higher material costs and tariffs have impacted gross margins.
• Creditors: Mortgage loans from Bank of America are secured by company properties. Liquidity is deemed sufficient for the next 12 months.

Next Steps

• Continue to ramp up production to fulfill increased backlog.
• Management will continue to consider additional share repurchases under the existing program.
• May seek out acquisitions and additional product lines.
• May invest a portion of cash into common stocks or higher yielding debt instruments to utilize net operating loss carryforwards.
• Remediate and test the effectiveness of controls related to the material weakness in internal control over financial reporting.

Key Dates

Recommendation

The company presents a mixed financial picture. The substantial increase in backlog and strong Q3 sales growth are positive indicators for future revenue. However, the significant decline in nine-month net income and operating income, coupled with margin compression due to higher material costs and tariffs, raises concerns about sustained profitability. The un-remediated material weakness in internal controls also adds a layer of risk. Given the strong future revenue potential from the backlog but current profitability challenges and governance concerns, a 'hold' recommendation is appropriate until there is clearer evidence of consistent profitability improvement and remediation of internal control issues.

Keywords

Semiconductor components, Military and aerospace, Solid-state devices, Power transistors, MOSFETs, Corporate governance, Financial reporting, SEC filing, 10-Q, Solitron Devices, Micro Engineering Inc., Government contracts, Backlog, Earnings, Revenue, Gross profit, Operating income, Cash flow, Stock repurchase, Customer concentration, Supply chain risk, Tariffs, Internal controls